FindMyKOL
Clinical trialNCT02262910CompletedPhase 1Interventional

Study of ES414 in Metastatic Castration-Resistant Prostate Cancer

SponsorAptevo TherapeuticsEnrollment35Prostate Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The study will be conducted in 2 Stages. The primary objective of Stage 1 of the study is to identify the maximum tolerated dose (MTD) of ES414 administered intravenously to patients with mCRPC. Secondary objectives are to evaluate the tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, cytokine response, and clinical activity of ES414. The primary objective of Stage 2 of the study is to evaluate the clinical activity of ES414 in patients that have or have not received prior chemotherapy. Secondary objectives are to further characterize the safety profile, PK, PD, and immunogenicity of ES414.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • St. Vincent'S Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Peter Maccallum Cancer Centre

    East Melbourne, Victoria, Australia

United States
  • University of California

    San Francisco, California, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, United States

  • Central Texas Veterans Health Care System

    Temple, Texas, United States

  • University of Washington/seattle Cancer Care Alliance

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ES414
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jan 2015
Primary completion
31 Dec 2018
Completion
18 Feb 2019
Last update posted
28 Aug 2019
Registered enrollment
35
Registry id
NCT02262910
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.